CAR T-cell therapy is a major advance in the treatment of individuals with non-Hodgkin lymphoma, especially for adult patients with relapsed or refractory large B-cell lymphoma. Several CAR-T therapies are now approved for second-line treatment, and data regarding their efficacy, safety, and real-world outcomes continue to emerge. Collaboration among hematologic oncology clinicians is needed to ensure that appropriate patients are referred for evaluation for CAR-T therapy earlier in their treatment journey, potentially offering them a better chance for lasting remission or even a cure.
During Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas, expert cell therapists and a community oncologist, along with several special guests, will highlight the clinical implications of the most recent data on CAR-T therapy, dispel myths and overcome misperceptions about access to and logistics associated with therapy, and answer your questions regarding referral and shared care. The interactive breakfast symposium, brought to you by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society, will be certified for 1.5 CME credit/EACCME reciprocal credits/contact hours for physicians, physician assistants, nurses, and pharmacists and will offer American Board of Internal Medicine Maintenance of Certification points. Don’t miss this exciting symposium—register TODAY to reserve your spot!
This CE activity is intended for hematologic oncology clinicians who provide care for individuals with aggressive B-cell lymphomas who may be candidates for CAR-T therapy.
After completing this CE activity, the participant should be better able to:
- Assess the clinical implications of recent and emerging safety and efficacy data for CAR-T therapies
- Evaluate the implications of recent and emerging data for referring clinicians
- Respond to common questions from and misperceptions of referring clinicians
- Collaborate with the inter-professional team to facilitate logistics and access for referred patients
- Plan strategies to participate in effective shared care with referring clinicians
Accreditation, Support and Credit Statements
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This CE activity is supported through an educational grant from Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 0.3 contact hours in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-058-L01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.
Educational Partner Statement
This activity is developed with our educational partner, The Leukemia & Lymphoma Society